tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
PremiumRatingsEnliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating
1M ago
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
Premium
Ratings
Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment
1M ago
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
Premium
The Fly
Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
1M ago
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
PremiumRatingsEnliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
4M ago
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
Premium
Ratings
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
4M ago
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
Premium
Company Announcements
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
4M ago
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
PremiumCompany AnnouncementsEnliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
5M ago
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
Premium
Company Announcements
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
5M ago
Enliven price target raised to $48 from $40 at H.C. Wainwright
Premium
The Fly
Enliven price target raised to $48 from $40 at H.C. Wainwright
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100